The influence of intraoperative tumor rupture on recurrencerisk in Stage Ic epithelial ovarian cancer

Objective: To characterize the Outcomes of patients with Stage Ic epithelial ovarian carcinoma, taking into consideration the criteria that were used to assign staging. We hypothesized that tumor rupture is a less ominous prognosticator in early-stage epithelial ovarian cancer than malignant washings or ovarian surface invasion. Methods: A retrospective analysis of patients diagnosed with Stage I epithelial ovarian carcinoma at the University of Minnesota between 1990 and 2005 was carried Out. Information was collected about demographics. diagnosis date. stage, grade, adjuvant treatment,w last contact date and Status at last Contact. Statistical analysis was performed using the Kaplan-Meier method and the Cox proportion hazard model. Results: One hundred and seventeen patients with Stage I epithelial ovarian cancer were identified and included in this review. Three distinct groups of patients were considered: I) patients with Stage Ic cancers, so-assigned because of intraoperative tumor rupture only, 2) patients with Stage Ic cancers. so-assigned for any other reason(s) than rupture alone, and 3) patients with Stages la and Ib cancers. The recurrence risk of patients in group I was not significantly different from that of patients in groups 2 or 3 (p values 0.13 and 0.69, respectively), although a trend toward decreased risk of recurrence was seen in patients from group I compared to both other groups. Conclusions: In our cohort of patients. the risk of tumor recurrence in patients with Stage Ic epithelial ovarian cancer, so-assigned because of intraoperative rupture alone. is not significantly different from the two other groups of patients with Stage I disease.

Epithelial ovarian cancer; Intraoperative tumor rupture; Stage Ic ovarian cancer

[1] Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A. et al.: Cancer statistics, 2005. C.A. Cancer J. Clin. , 2005, 55, 259.

[2] Petterson F., Coppleson M., Creasman W., Ludwig H., ShepherdJ.H.: Annual report on the results of treatment in gynecologic cancer. Stockholm, International Federation of Gynecology and Obstetrics, 1988, Vol. 20.

[3] Sevelda P., Dittrich C., Salzer H.: Prognostic value of the rupture of the capsule in stage I epithelial ovarian carcinoma. Gynecol.Oncol. , 1989, 35, 321.

[4] Sevelda P., Vavra N., Schemper M., Salzar H.: Prognostic factors for survival in stage I epithelial ovarian carcinoma. Cancer, 1990, 65, 2349.

[5] Dembo A.J., Davy M., Stenwig A.E., Berle E.J., Bush R.S., Kjorstad K.: Prognostic factors in patients with stage I epithelial ovarian cancer. Obstet. Gynecol. , 1990, 75, 263.

[6] Sjovall K., Nilsson B., Einhorn N.: Different types of rupture of the tumor capsule and impact on survival in early ovarian carcinoma. Int. J. Gynecol. Cancer, 1994, 4, 333.

[7] Ahmed F.Y., Wiltshaw E., Ahern R.P., Nicol B., Shepherd J., Blake P. et al.: Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J. Clin. Oncol. , 1996, 14, 2968.

[8] Kodama S., Tanaka K., Tokunaga A., Sudo N., Takahashi T., Matsui K.: Multivariate analysis of prognostic factors in patients with ovarian cancer stage I and II. Int. J. Gynaecol. Obstet. , 1997, 56, 147.

[9] Leitao M.M., Boyd J., Hummer A., Olvera N., Arroyo C.D., Venkatraman E. et al.: Clinicopathologic analysis of early-stage sporadic ovarian carcinoma. Am. J. Surg. Pathol. , 2004, 28, 147.

[10] Sainz de la Cuesta R., Goff B.A., Fuller A.F., Nikrui N., EichhornJ.H. , Rice L.W.: Prognostic importance of intraoperative rupture of malignant ovarian epithelial neoplasms. Obstet. Gynecol.1994, 84, 1.

[11] Vergote I., DeBrabanter J., Fyles A., Bertelsen K., Einhorn N.,Sevelda P. et al.: Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet, 2001, 357, 176.

[12] Mizuno M., Kikkawa F., Shibata K., Kajiyama H., Suzuki T., InoK. et al.: Long-term prognosis of stage I ovarian carcinoma. Oncology, 2003, 65, 29.

[13] Trimbos J.B., Vergote I., Bolis G., Vermorken J.B., Mangioni C., Madronal C. et al.: Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organization for research and treatment of cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm Trial. J. Natl. Cancer Inst., 2003, 95, 113.

[14] International Collaborative Ovarian Neoplasm Trial 1: a randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J. Natl. Cancer Inst., 2003, 95, 125.

[15] International Collaborative Ovarian Neoplasm Trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm Trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J. Natl. Cancer Inst., 2003, 95,105.

[16] Winter-Roach B, Hooper L, Kitchener H.: Systematic review of adjuvant therapy for early stage (epithelial) ovarian cancer. Int. J.Gyncol. Cancer, 2003, 13, 395.

[17] Vergote I., Trimbos J.B.: Treatment of patients with early epithelia ovarian cancer. Curr. Opin. Oncol. , 2003, 15, 452.

[18] Trimbos J.B., Timmers P.: Chemotherapy for early ovarian cancer. Curr. Opin. Obstet. Gynecol. , 2004, 16, 43.